Chemical Safety & Toxicology Assessment
Toxicity assessment: identify the chemical, check known hazards (GHS, IARC), then look for ADMET predictions. Dose makes the poison — always consider exposure level, as a compound that is toxic at high doses may be safe at relevant exposures. Distinguish between acute toxicity (LD50, GHS category) and chronic hazards (carcinogenicity, endocrine disruption) — they require different risk management approaches. Computational predictions (ADMETAI) are T3 evidence and must be anchored by experimental data from PubChemTox or FDA labels wherever available. When evidence conflicts between prediction and experiment, always defer to the experimental finding.
LOOK UP DON'T GUESS: never assume GHS categories, IARC classification, or CTD disease links — always call PubChemTox and CTD tools to retrieve current classifications before reporting.
Comprehensive chemical safety analysis integrating predictive AI models, curated toxicogenomics databases, regulatory safety data, and chemical-biological interaction networks.
When to Use This Skill
Triggers:
- "Is this chemical toxic?" / "Assess the safety profile of [drug/chemical]"
- "What are the ADMET properties of [SMILES]?"
- "What genes does [chemical] interact with?" / "What diseases are linked to [chemical] exposure?"
- "Drug safety assessment" / "Environmental health risk" / "Chemical hazard profiling"
Use Cases:
- Predictive Toxicology: AI-predicted endpoints (AMES, DILI, LD50, carcinogenicity, hERG) via SMILES
- ADMET Profiling: Absorption, distribution, metabolism, excretion, toxicity
- Toxicogenomics: Chemical-gene-disease mapping from CTD
- Regulatory Safety: FDA label warnings, contraindications, adverse reactions
- Drug Safety: DrugBank safety + FDA labels combined
- Chemical-Protein Interactions: STITCH-based interaction networks
- Environmental Toxicology: Chemical-disease associations for contaminants
COMPUTE, DON'T DESCRIBE
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.
KEY PRINCIPLES
- Report-first approach - Create report file FIRST, then populate progressively
- Tool parameter verification - Verify params via
get_tool_info before calling unfamiliar tools
- Evidence grading - Grade all safety claims by evidence strength (T1-T4)
- Citation requirements - Every toxicity finding must have inline source attribution
- Mandatory completeness - All sections must exist with data or explicit "No data" notes
- Disambiguation first - Resolve compound identity (name -> SMILES, CID, ChEMBL ID) before analysis
- Negative results documented - "No toxicity signals found" is data; empty sections are failures
- Conservative risk assessment - When evidence is ambiguous, flag as "requires further investigation"
- English-first queries - Always use English chemical/drug names in tool calls
Evidence Grading System (MANDATORY)
| Tier |
Symbol |
Criteria |
Examples |
| T1 |
[T1] |
Direct human evidence, regulatory finding |
FDA boxed warning, clinical trial toxicity |
| T2 |
[T2] |
Animal studies, validated in vitro |
Nonclinical toxicology, AMES positive, animal LD50 |
| T3 |
[T3] |
Computational prediction, association data |
ADMET-AI prediction, CTD association |
| T4 |
[T4] |
Database annotation, text-mined |
Literature mention, unvalidated database entry |
Evidence grades MUST appear in: Executive Summary, Toxicity Predictions, Regulatory Safety, Chemical-Gene Interactions, Risk Assessment.
Core Strategy: 8 Research Phases
Chemical/Drug Query
|
+-- PHASE 0: Compound Disambiguation (ALWAYS FIRST)
| Resolve name -> SMILES, PubChem CID, ChEMBL ID, formula, weight
|
+-- PHASE 1: Predictive Toxicology (ADMET-AI)
| AMES, DILI, ClinTox, carcinogenicity, LD50, hERG, skin reaction
| Stress response pathways, nuclear receptor activity
|
+-- PHASE 2: ADMET Properties
| BBB penetrance, bioavailability, clearance, CYP interactions, physicochemical
|
+-- PHASE 3: Toxicogenomics (CTD)
| Chemical-gene interactions, chemical-disease associations
|
+-- PHASE 4: Regulatory Safety (FDA Labels)
| Boxed warnings, contraindications, adverse reactions, nonclinical tox
|
+-- PHASE 5: Drug Safety Profile (DrugBank)
| Toxicity data, contraindications, drug interactions
|
+-- PHASE 6: Chemical-Protein Interactions (STITCH)
| Direct binding, off-target effects, interaction confidence
|
+-- PHASE 7: Structural Alerts (ChEMBL)
| PAINS, Brenk, Glaxo structural alerts
|
+-- SYNTHESIS: Integrated Risk Assessment
Risk classification, evidence summary, data gaps, recommendations
See phase-procedures-detailed.md for complete tool parameters, decision logic, output templates, and fallback strategies for each phase.
Tool Summary by Phase
Phase 0: Compound Disambiguation
PubChem_get_CID_by_compound_name (name: str)
PubChem_get_compound_properties_by_CID (cid: int)
ChEMBL_get_molecule (if ChEMBL ID available)
Phase 1: Predictive Toxicology
Dependency: ADMET-AI tools require pip install tooluniverse[ml]. If unavailable, skip to Phase 3 and use CTD + PubChemTox as alternatives.
ADMETAI_predict_toxicity (smiles: list[str]) - AMES, DILI, ClinTox, LD50, hERG, etc.
ADMETAI_predict_stress_response (smiles: list[str])
ADMETAI_predict_nuclear_receptor_activity (smiles: list[str])
Phase 2: ADMET Properties
ADMETAI_predict_BBB_penetrance / _bioavailability / _clearance_distribution / _CYP_interactions / _physicochemical_properties / _solubility_lipophilicity_hydration (all take smiles: list[str])
Phase 3: Toxicogenomics
CTD_get_chemical_gene_interactions (input_terms: str) — chemical name, returns gene interactions across species
CTD_get_chemical_diseases (input_terms: str) — chemical-disease associations with evidence type
Phase 3.5: PubChem Toxicity Data
PubChemTox_get_toxicity_values (cid: int) — LD50, LC50, NOAEL reference values
PubChemTox_get_ghs_classification (cid: int) — GHS hazard classification and pictograms
PubChemTox_get_carcinogen_classification (cid: int) — NTP/IARC carcinogenicity assessments
PubChemTox_get_acute_effects (cid: int) — acute toxicity by route/species
PubChemTox_get_toxicity_summary (cid: int) — integrated toxicity overview
Phase 3.6: Adverse Outcome Pathways
AOPWiki_list_aops (keyword: str) — search for relevant AOPs by chemical/mechanism
AOPWiki_get_aop (aop_id: int) — full AOP detail: MIE, key events, adverse outcome
Phase 3.7: Environmental Exposure Context (US facilities)
Use for exposure/environmental-justice screening — locate regulated facilities near a community before assessing population-level exposure.
EPA_search_tri_facilities (state, city, limit) — Toxics Release Inventory facilities reporting toxic chemical releases
EPA_search_frs_facilities (state, city, limit) — Facility Registry Service (all EPA-regulated facilities) for broader siting/permitting context
Phase 4: Regulatory Safety (for pharmaceuticals only)
Environmental chemicals: Skip Phases 4-5 (no FDA labels/DrugBank). Use CTD + PubChemTox + AOPWiki instead.
FDA_get_boxed_warning_info_by_drug_name / _contraindications_ / _adverse_reactions_ / _warnings_ (all take drug_name: str)
Phase 5: Drug Safety (for pharmaceuticals only)
drugbank_get_safety_by_drug_name_or_drugbank_id (query, case_sensitive, exact_match, limit - all 4 required)
Phase 6: Chemical-Protein Interactions
STITCH_get_chemical_protein_interactions (identifiers: list[str], species: int)
- Fallback (if STITCH fails for industrial chemicals):
STRING_get_interaction_partners for key target genes (e.g., ESR1 for endocrine disruptors)
DGIdb_get_drug_gene_interactions (genes: list[str]) — for target druggability context
Phase 7: Structural Alerts
ChEMBL_search_compound_structural_alerts (molecule_chembl_id: str)
Risk Classification Matrix
| Risk Level |
Criteria |
| CRITICAL |
FDA boxed warning OR multiple [T1] toxicity findings OR active DILI + active hERG |
| HIGH |
FDA warnings OR [T2] animal toxicity OR multiple active ADMET endpoints |
| MEDIUM |
Some [T3] predictions positive OR CTD disease associations OR structural alerts |
| LOW |
All ADMET endpoints negative AND no FDA/DrugBank flags AND no CTD concerns |
| INSUFFICIENT DATA |
Fewer than 3 phases returned data |
Report Structure
# Chemical Safety & Toxicology Report: [Compound Name]
**Generated**: YYYY-MM-DD | **SMILES**: [...] | **CID**: [...]
## Executive Summary (risk classification + key findings, all graded)
## 1. Compound Identity (disambiguation table)
## 2. Predictive Toxicology (ADMET-AI endpoints)
## 3. ADMET Profile (absorption, distribution, metabolism, excretion)
## 4. Toxicogenomics (CTD chemical-gene-disease)
## 5. Regulatory Safety (FDA label data)
## 6. Drug Safety Profile (DrugBank)
## 7. Chemical-Protein Interactions (STITCH network)
## 8. Structural Alerts (ChEMBL)
## 9. Integrated Risk Assessment (classification, evidence summary, gaps, recommendations)
## Appendix: Methods and Data Sources
See report-templates.md for full section templates with example tables.
Mandatory Completeness Checklist
Common Use Patterns
- Novel Compound: SMILES -> Phase 0 (resolve) -> Phase 1 (toxicity) -> Phase 2 (ADMET) -> Phase 7 (structural alerts) -> Synthesis
- Approved Drug Review: Drug name -> All phases (0-7) -> Complete safety dossier
- Environmental Chemical: Chemical name -> Phase 0 -> Phase 1-2 -> Phase 3 (CTD, key) -> Phase 6 (STITCH) -> Synthesis
- Batch Screening: Multiple SMILES -> Phase 0 -> Phase 1-2 (batch) -> Comparative table -> Synthesis
- Toxicogenomic Deep-Dive: Chemical + gene/disease interest -> Phase 0 -> Phase 3 (expanded CTD) -> Literature -> Synthesis
Limitations
- ADMET-AI: Computational [T3]; should not replace experimental testing
- CTD: May lag behind latest literature by 6-12 months
- FDA: Only covers FDA-approved drugs; not applicable to environmental chemicals
- DrugBank: Primarily drugs; limited industrial chemical coverage
- STITCH: Lower score thresholds increase false positives
- ChEMBL: Structural alerts require ChEMBL ID; not all compounds have one
- Novel compounds: May only have ADMET-AI predictions (no database evidence)
- SMILES validity: Invalid SMILES cause ADMET-AI failures
Reference Files
- phase-procedures-detailed.md - Complete tool parameters, decision logic, output templates, fallback strategies per phase
- evidence-grading.md - Evidence grading details and examples
- report-templates.md - Full report section templates with example tables
- phase-details.md - Additional phase context
- test_skill.py - Test suite
Summary
Total tools integrated: 25+ tools across 6 databases (ADMET-AI, CTD, FDA, DrugBank, STITCH, ChEMBL)
Best for: Drug safety assessment, chemical hazard profiling, environmental toxicology, ADMET characterization, toxicogenomic analysis
Outputs: Structured markdown report with risk classification (Critical/High/Medium/Low), evidence grading [T1-T4], and actionable recommendations
1---2name: tooluniverse-chemical-safety3description: Chemical safety and toxicology assessment integrating ADMET-AI predictions, CTD toxicogenomics, PubChemTox experimental data, GHS/IARC hazard classification, and exposure-context analysis. Use for chemical hazard identification, occupational/consumer-product toxicity, dose-response evaluation, and acute (LD50) vs chronic toxicity assessment. Distinguishes drug toxicity from environmental chemical toxicity.4---5
6# Chemical Safety & Toxicology Assessment
7
8**Toxicity assessment**: identify the chemical, check known hazards (GHS, IARC), then look for ADMET predictions. Dose makes the poison — always consider exposure level, as a compound that is toxic at high doses may be safe at relevant exposures. Distinguish between acute toxicity (LD50, GHS category) and chronic hazards (carcinogenicity, endocrine disruption) — they require different risk management approaches. Computational predictions (ADMETAI) are T3 evidence and must be anchored by experimental data from PubChemTox or FDA labels wherever available. When evidence conflicts between prediction and experiment, always defer to the experimental finding.
9
10**LOOK UP DON'T GUESS**: never assume GHS categories, IARC classification, or CTD disease links — always call PubChemTox and CTD tools to retrieve current classifications before reporting.
11
12Comprehensive chemical safety analysis integrating predictive AI models, curated toxicogenomics databases, regulatory safety data, and chemical-biological interaction networks.
13
14## When to Use This Skill
15
16**Triggers**:
17- "Is this chemical toxic?" / "Assess the safety profile of [drug/chemical]"
18- "What are the ADMET properties of [SMILES]?"
19- "What genes does [chemical] interact with?" / "What diseases are linked to [chemical] exposure?"
20- "Drug safety assessment" / "Environmental health risk" / "Chemical hazard profiling"
21
22**Use Cases**:
231. **Predictive Toxicology**: AI-predicted endpoints (AMES, DILI, LD50, carcinogenicity, hERG) via SMILES
242. **ADMET Profiling**: Absorption, distribution, metabolism, excretion, toxicity
253. **Toxicogenomics**: Chemical-gene-disease mapping from CTD
264. **Regulatory Safety**: FDA label warnings, contraindications, adverse reactions
275. **Drug Safety**: DrugBank safety + FDA labels combined
286. **Chemical-Protein Interactions**: STITCH-based interaction networks
297. **Environmental Toxicology**: Chemical-disease associations for contaminants
30
31---
32
33## COMPUTE, DON'T DESCRIBE
34When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.
35
36## KEY PRINCIPLES
37
381. **Report-first approach** - Create report file FIRST, then populate progressively
392. **Tool parameter verification** - Verify params via `get_tool_info` before calling unfamiliar tools
403. **Evidence grading** - Grade all safety claims by evidence strength (T1-T4)
414. **Citation requirements** - Every toxicity finding must have inline source attribution
425. **Mandatory completeness** - All sections must exist with data or explicit "No data" notes
436. **Disambiguation first** - Resolve compound identity (name -> SMILES, CID, ChEMBL ID) before analysis
447. **Negative results documented** - "No toxicity signals found" is data; empty sections are failures
458. **Conservative risk assessment** - When evidence is ambiguous, flag as "requires further investigation"
469. **English-first queries** - Always use English chemical/drug names in tool calls
47
48---
49
50## Evidence Grading System (MANDATORY)
51
52| Tier | Symbol | Criteria | Examples |
53|------|--------|----------|----------|
54| **T1** | [T1] | Direct human evidence, regulatory finding | FDA boxed warning, clinical trial toxicity |
55| **T2** | [T2] | Animal studies, validated in vitro | Nonclinical toxicology, AMES positive, animal LD50 |
56| **T3** | [T3] | Computational prediction, association data | ADMET-AI prediction, CTD association |
57| **T4** | [T4] | Database annotation, text-mined | Literature mention, unvalidated database entry |
58
59Evidence grades MUST appear in: Executive Summary, Toxicity Predictions, Regulatory Safety, Chemical-Gene Interactions, Risk Assessment.
60
61---
62
63## Core Strategy: 8 Research Phases
64
65```
66Chemical/Drug Query
67|
68+-- PHASE 0: Compound Disambiguation (ALWAYS FIRST)
69| Resolve name -> SMILES, PubChem CID, ChEMBL ID, formula, weight
70|
71+-- PHASE 1: Predictive Toxicology (ADMET-AI)
72| AMES, DILI, ClinTox, carcinogenicity, LD50, hERG, skin reaction
73| Stress response pathways, nuclear receptor activity
74|
75+-- PHASE 2: ADMET Properties
76| BBB penetrance, bioavailability, clearance, CYP interactions, physicochemical
77|
78+-- PHASE 3: Toxicogenomics (CTD)
79| Chemical-gene interactions, chemical-disease associations
80|
81+-- PHASE 4: Regulatory Safety (FDA Labels)
82| Boxed warnings, contraindications, adverse reactions, nonclinical tox
83|
84+-- PHASE 5: Drug Safety Profile (DrugBank)
85| Toxicity data, contraindications, drug interactions
86|
87+-- PHASE 6: Chemical-Protein Interactions (STITCH)
88| Direct binding, off-target effects, interaction confidence
89|
90+-- PHASE 7: Structural Alerts (ChEMBL)
91| PAINS, Brenk, Glaxo structural alerts
92|
93+-- SYNTHESIS: Integrated Risk Assessment
94 Risk classification, evidence summary, data gaps, recommendations
95```
96
97See **phase-procedures-detailed.md** for complete tool parameters, decision logic, output templates, and fallback strategies for each phase.
98
99---
100
101## Tool Summary by Phase
102
103### Phase 0: Compound Disambiguation
104- `PubChem_get_CID_by_compound_name` (`name`: str)
105- `PubChem_get_compound_properties_by_CID` (`cid`: int)
106- `ChEMBL_get_molecule` (if ChEMBL ID available)
107
108### Phase 1: Predictive Toxicology
109> **Dependency**: ADMET-AI tools require `pip install tooluniverse[ml]`. If unavailable, skip to Phase 3 and use CTD + PubChemTox as alternatives.
110
111- `ADMETAI_predict_toxicity` (`smiles`: list[str]) - AMES, DILI, ClinTox, LD50, hERG, etc.
112- `ADMETAI_predict_stress_response` (`smiles`: list[str])
113- `ADMETAI_predict_nuclear_receptor_activity` (`smiles`: list[str])
114
115### Phase 2: ADMET Properties
116- `ADMETAI_predict_BBB_penetrance` / `_bioavailability` / `_clearance_distribution` / `_CYP_interactions` / `_physicochemical_properties` / `_solubility_lipophilicity_hydration` (all take `smiles`: list[str])
117
118### Phase 3: Toxicogenomics
119- `CTD_get_chemical_gene_interactions` (`input_terms`: str) — chemical name, returns gene interactions across species
120- `CTD_get_chemical_diseases` (`input_terms`: str) — chemical-disease associations with evidence type
121
122### Phase 3.5: PubChem Toxicity Data
123- `PubChemTox_get_toxicity_values` (`cid`: int) — LD50, LC50, NOAEL reference values
124- `PubChemTox_get_ghs_classification` (`cid`: int) — GHS hazard classification and pictograms
125- `PubChemTox_get_carcinogen_classification` (`cid`: int) — NTP/IARC carcinogenicity assessments
126- `PubChemTox_get_acute_effects` (`cid`: int) — acute toxicity by route/species
127- `PubChemTox_get_toxicity_summary` (`cid`: int) — integrated toxicity overview
128
129### Phase 3.6: Adverse Outcome Pathways
130- `AOPWiki_list_aops` (`keyword`: str) — search for relevant AOPs by chemical/mechanism
131- `AOPWiki_get_aop` (`aop_id`: int) — full AOP detail: MIE, key events, adverse outcome
132
133### Phase 3.7: Environmental Exposure Context (US facilities)
134> Use for exposure/environmental-justice screening — locate regulated facilities near a community before assessing population-level exposure.
135- `EPA_search_tri_facilities` (`state`, `city`, `limit`) — Toxics Release Inventory facilities reporting toxic chemical releases
136- `EPA_search_frs_facilities` (`state`, `city`, `limit`) — Facility Registry Service (all EPA-regulated facilities) for broader siting/permitting context
137
138### Phase 4: Regulatory Safety (for pharmaceuticals only)
139> **Environmental chemicals**: Skip Phases 4-5 (no FDA labels/DrugBank). Use CTD + PubChemTox + AOPWiki instead.
140
141- `FDA_get_boxed_warning_info_by_drug_name` / `_contraindications_` / `_adverse_reactions_` / `_warnings_` (all take `drug_name`: str)
142
143### Phase 5: Drug Safety (for pharmaceuticals only)
144- `drugbank_get_safety_by_drug_name_or_drugbank_id` (`query`, `case_sensitive`, `exact_match`, `limit` - all 4 required)
145
146### Phase 6: Chemical-Protein Interactions
147- `STITCH_get_chemical_protein_interactions` (`identifiers`: list[str], `species`: int)
148- **Fallback** (if STITCH fails for industrial chemicals): `STRING_get_interaction_partners` for key target genes (e.g., ESR1 for endocrine disruptors)
149- `DGIdb_get_drug_gene_interactions` (`genes`: list[str]) — for target druggability context
150
151### Phase 7: Structural Alerts
152- `ChEMBL_search_compound_structural_alerts` (`molecule_chembl_id`: str)
153
154---
155
156## Risk Classification Matrix
157
158| Risk Level | Criteria |
159|-----------|----------|
160| **CRITICAL** | FDA boxed warning OR multiple [T1] toxicity findings OR active DILI + active hERG |
161| **HIGH** | FDA warnings OR [T2] animal toxicity OR multiple active ADMET endpoints |
162| **MEDIUM** | Some [T3] predictions positive OR CTD disease associations OR structural alerts |
163| **LOW** | All ADMET endpoints negative AND no FDA/DrugBank flags AND no CTD concerns |
164| **INSUFFICIENT DATA** | Fewer than 3 phases returned data |
165
166---
167
168## Report Structure
169
170```
171# Chemical Safety & Toxicology Report: [Compound Name]
172**Generated**: YYYY-MM-DD | **SMILES**: [...] | **CID**: [...]
173
174## Executive Summary (risk classification + key findings, all graded)
175## 1. Compound Identity (disambiguation table)
176## 2. Predictive Toxicology (ADMET-AI endpoints)
177## 3. ADMET Profile (absorption, distribution, metabolism, excretion)
178## 4. Toxicogenomics (CTD chemical-gene-disease)
179## 5. Regulatory Safety (FDA label data)
180## 6. Drug Safety Profile (DrugBank)
181## 7. Chemical-Protein Interactions (STITCH network)
182## 8. Structural Alerts (ChEMBL)
183## 9. Integrated Risk Assessment (classification, evidence summary, gaps, recommendations)
184## Appendix: Methods and Data Sources
185```
186
187See **report-templates.md** for full section templates with example tables.
188
189---
190
191## Mandatory Completeness Checklist
192
193- [ ] Phase 0: Compound disambiguated (SMILES + CID minimum)
194- [ ] Phase 1: At least 5 toxicity endpoints or "prediction unavailable"
195- [ ] Phase 2: ADMET A/D/M/E sections or "not available"
196- [ ] Phase 3: CTD queried; results or "no data in CTD"
197- [ ] Phase 4: FDA labels queried; results or "not FDA-approved"
198- [ ] Phase 5: DrugBank queried; results or "not found"
199- [ ] Phase 6: STITCH queried; results or "no data available"
200- [ ] Phase 7: Structural alerts checked or "ChEMBL ID not available"
201- [ ] Synthesis: Risk classification with evidence summary
202- [ ] Evidence Grading: All findings have [T1]-[T4] annotations
203- [ ] Data Gaps: Explicitly listed
204
205---
206
207## Common Use Patterns
208
2091. **Novel Compound**: SMILES -> Phase 0 (resolve) -> Phase 1 (toxicity) -> Phase 2 (ADMET) -> Phase 7 (structural alerts) -> Synthesis
2102. **Approved Drug Review**: Drug name -> All phases (0-7) -> Complete safety dossier
2113. **Environmental Chemical**: Chemical name -> Phase 0 -> Phase 1-2 -> Phase 3 (CTD, key) -> Phase 6 (STITCH) -> Synthesis
2124. **Batch Screening**: Multiple SMILES -> Phase 0 -> Phase 1-2 (batch) -> Comparative table -> Synthesis
2135. **Toxicogenomic Deep-Dive**: Chemical + gene/disease interest -> Phase 0 -> Phase 3 (expanded CTD) -> Literature -> Synthesis
214
215---
216
217## Limitations
218
219- **ADMET-AI**: Computational [T3]; should not replace experimental testing
220- **CTD**: May lag behind latest literature by 6-12 months
221- **FDA**: Only covers FDA-approved drugs; not applicable to environmental chemicals
222- **DrugBank**: Primarily drugs; limited industrial chemical coverage
223- **STITCH**: Lower score thresholds increase false positives
224- **ChEMBL**: Structural alerts require ChEMBL ID; not all compounds have one
225- **Novel compounds**: May only have ADMET-AI predictions (no database evidence)
226- **SMILES validity**: Invalid SMILES cause ADMET-AI failures
227
228---
229
230## Reference Files
231
232- **phase-procedures-detailed.md** - Complete tool parameters, decision logic, output templates, fallback strategies per phase
233- **evidence-grading.md** - Evidence grading details and examples
234- **report-templates.md** - Full report section templates with example tables
235- **phase-details.md** - Additional phase context
236- **test_skill.py** - Test suite
237
238---
239
240## Summary
241
242**Total tools integrated**: 25+ tools across 6 databases (ADMET-AI, CTD, FDA, DrugBank, STITCH, ChEMBL)
243
244**Best for**: Drug safety assessment, chemical hazard profiling, environmental toxicology, ADMET characterization, toxicogenomic analysis
245
246**Outputs**: Structured markdown report with risk classification (Critical/High/Medium/Low), evidence grading [T1-T4], and actionable recommendations